Cognitive enhancement as a pharmacotherapy target for stimulant addiction

被引:133
作者
Sofuoglu, Mehmet [1 ]
机构
[1] Yale Univ, Sch Med, Dept Psychiat, VA Connecticut Healthcare Syst, West Haven, CT 06516 USA
关键词
Cognition; cognitive enhancers; pharmacotherapy; stimulants; WORKING-MEMORY PERFORMANCE; STOP SIGNAL INHIBITION; RESPONSE-INHIBITION; PREFRONTAL CORTEX; COCAINE DEPENDENCE; CHOLINESTERASE-INHIBITORS; EXTRACELLULAR DOPAMINE; INDUCED REINSTATEMENT; NUCLEUS-ACCUMBENS; LOCUS-CERULEUS;
D O I
10.1111/j.1360-0443.2009.02791.x
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background No medications have been proven to be effective for cocaine and methamphetamine addiction. Attenuation of drug reward has been the main strategy for medications development, but this approach has not led to effective treatments. Thus, there is a need to identify novel treatment targets in addition to the brain reward system. Aim To propose a novel treatment strategy for stimulant addiction that will focus on medications enhancing cognitive function and attenuating drug reward. Methods Pre-clinical and clinical literature on potential use of cognitive enhancers for stimulant addiction pharmacotherapy was reviewed. Results and conclusions Cocaine and methamphetamine users show significant cognitive impairments, especially in attention, working memory and response inhibition functions. The cognitive impairments seem to be predictive of poor treatment retention and outcome. Medications targeting acetylcholine and norepinephrine are particularly well suited for enhancing cognitive function in stimulant users. Many cholinergic and noradrenergic medications are on the market and have a good safety profile and low abuse potential. These include galantamine, donepezil and rivastigmine (cholinesterase inhibitors), varenicline (partial nicotine agonist), guanfacine (alpha(2)-adrenergic agonist) and atomoxetine (norepinephrine transporter inhibitor). Future clinical studies designed optimally to measure cognitive function as well as drug use behavior would be needed to test the efficacy of these cognitive enhancers for stimulant addiction.
引用
收藏
页码:38 / 48
页数:11
相关论文
共 133 条
[1]   Cognitive deficits predict low treatment retention in cocaine dependent patients [J].
Aharonovich, E ;
Hasin, DS ;
Brooks, AC ;
Liu, XH ;
Bisaga, A ;
Nunes, EV .
DRUG AND ALCOHOL DEPENDENCE, 2006, 81 (03) :313-322
[2]   Cognitive impairment, retention and abstinence among cocaine abusers in cognitive-behavioral treatment [J].
Aharonovich, E ;
Nunes, E ;
Hasin, D .
DRUG AND ALCOHOL DEPENDENCE, 2003, 71 (02) :207-211
[3]  
[Anonymous], 2008, WORLD DRUG REP
[4]   Stimulants: Therapeutic actions in ADHD [J].
Arnsten, Amy F. T. .
NEUROPSYCHOPHARMACOLOGY, 2006, 31 (11) :2376-2383
[5]   Location, location: using functional magnetic resonance imaging to pinpoint brain differences relevant to stimulant use [J].
Aron, Jennifer L. ;
Paulus, Martin P. .
ADDICTION, 2007, 102 :33-43
[6]   Cognitive impairment influences drinking outcome by altering therapeutic mechanisms of change [J].
Bates, Marsha E. ;
Pawlak, Anthony P. ;
Tonigan, J. Scott ;
Buckman, Jennifer F. .
PSYCHOLOGY OF ADDICTIVE BEHAVIORS, 2006, 20 (03) :241-253
[7]   Cholinergic interneurons of the nucleus accumbens and dorsal striatum are activated by the self-administration of cocaine [J].
Berlanga, ML ;
Olsen, CM ;
Chen, V ;
Ikegami, A ;
Herring, BE ;
Duvauchelle, CL ;
Alcantara, AA .
NEUROSCIENCE, 2003, 120 (04) :1149-1156
[8]   Cholinesterase inhibitors for Alzheimer's disease [J].
Birks, J .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (01)
[9]   Dose-related neurobehavioral effects of chronic cocaine use [J].
Bolla, KI ;
Rothman, R ;
Cadet, JL .
JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 1999, 11 (03) :361-369
[10]   Neuronal mechanisms underlying attention deficit hyperactivity disorder - The influence of arousal on prefrontal cortical function [J].
Brennan, Avis R. ;
Arnsten, Amy F. T. .
MOLECULAR AND BIOPHYSICAL MECHANISMS OF AROUSAL, ALERTNESS, AND ATTENTION, 2008, 1129 :236-245